Generic diabetes drug put to the test against Brand-Name synjardy XR

NCT ID NCT07266766

Completed Knowledge-focused Sponsor: Humanis Saglık Anonim Sirketi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study checks whether a generic version of the diabetes drug empagliflozin/metformin works the same as the brand-name Synjardy XR. Forty healthy adults each take one dose of both pills under fed conditions, and researchers compare how much drug gets into the bloodstream. The goal is to see if the generic is a suitable, lower-cost alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin and metformin extended-release tablets
What this could lead to: If successful, this could help bring a more affordable generic version of this diabetes medication to market.
What could go wrong: This is an early-phase bioequivalence study in only 40 healthy people, not patients. It does not test whether the drug works for diabetes, only that the generic matches the brand in absorption.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

Veeda Clinical Research Limited

Ahmedabad, Gujarat, 384205, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.